Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-37

And don't forget this from yesterday's report (page 39):

In addition to these patent applications, ResApp has an exclusive license of the know-how (and trade secrets) in the set of mathematical features and classifier technology used for the diagnosis and severity measurement of pneumonia, asthma and COPD developed by the research team at UQ.

While it is not ideal that the trial is continuing as a freebie, the data collected strengthens RAP's core IP which, in the long run, may be a lot more valuable than the patents as know-how and trade secrets do not necessarily have a fixed duration!